-
Human skeletal stem cells identified, may have therapeutic potential: 4 things to know
Researchers identified the human skeletal stem cell and derived it from induced pluripotent stem cells, according to findings published in Cell Stem Cell. -
Dr. Pablo Pazmino: Key thoughts on stem cells & new technology in spine surgery
Pablo Pazmino, MD, medical director of Spine Cal in Santa Monica, Calif., discusses the key trends in spinal and neurospine technology and how he evaluates new technology for his practice. -
Orthopedic surgeon performs case in Pluristem Therapeutics' stem cell trial: 4 insights
R. Brandon Trale, DO, performed a partial hip replacement case as part of a Pluristem Therapeutics stem cell trial at Indiana (Pa.) Regional Medical Center, according to The Indiana Gazette. -
NuVasive expands biologics portfolio with 3 new offerings
NuVasive launched three new biologics offerings for the spine industry. -
Regenexx makes new partnership to reduce musculoskeletal surgery costs
Cost management solutions company Tempus Innovations partnered with Regenexx to provide reduced-cost, non-surgical treatments to injured workers. -
10 leading players in the global orthopedic biomaterials market
Here are 10 key players in the global orthopedic biomaterials market, according to a Market iFrame report. -
Bioengineered ACL implant startup raises $22.5M: 4 things to know
MIACH Orthopaedics, a bioengineered surgical implant company, completed $22.5 million in financing. -
Spinal cord stem cells improve functional outcomes in animal SCI model: 3 study notes
UC San Diego researchers derived spinal cord neural stem cells from human pluripotent stem cells transplanted into a rat model with spinal cord injury, according to a study in Nature Methods. -
Smart injectable self-setting orthopedic implant biocompatible, study finds
University of Toledo (Ohio) researchers developed a smart injectable calcium phosphate bone cement for orthopedic and spinal fusion applications. The smart CaP compositions were biocompatible, according to a study in Materials. -
Regenexx affiliates with BICC to accelerate orthopedic stem cell treatments: 3 details
Best in Class Care entered an agreement with Regenexx to reduce high-cost musculoskeletal surgeries and accelerate employers' ability to directly contract with its network of providers. -
Seattle Regenerative Medicine Center opens new Washington state location: 3 notes
The Seattle Regenerative Medicine Center opened a new location in Bellevue, Wash. -
Baxter receives FDA clearance for bone graft substitute: 4 key notes
Baxter International received FDA clearance for its Actifuse Flow bone graft substitute. -
Dr. Mark Mikhael studies stem cells for spine surgery – 4 insights
Mark Mikhael, MD, is studying the use of proteins from donor stem cells in spinal fusion surgery, Chicago Health reports. -
Spine biologics market to exceed $2.6B by 2022: 3 observations
Market analysts predict the spine biologics market will top $2.6 billion by 2022, growing at a 4.4 percent compound annual growth rate, according to a Market Research Engine report. -
SpinalCyte receives new patent for cartilage repair: 3 insights
SpinalCyte received a U.S. patent for its cartilage repair technology using an in vivo bioreactor. -
Biologics in spine surgery holds great promise — Dr. Choll Kim shares insight into new field
While the use of biologics in spine surgery is still emerging, more spine surgeons are gaining exposure to the field as new clinical trials and noninvasive treatments are born. -
InVivo Therapeutics concludes INSPIRE study: 5 things to know
InVivo Therapeutics released the 12-month results of its investigational study of the Neuro-Spinal Scaffold to treat acute thoracic complete spinal cord injury. -
Organogenesis to merge to create $673M company: 4 notes
Avista Healthcare Public Acquisition will merge with the regenerative medicine company Organogenesis. -
6 things to know about Isto Biologics
Isto Biologics is an orthobiologics company that develops spine and orthopedic solutions. -
Biologics may reduce work & activity impairment in axial spondyloarthritis patients, study shows: 4 things to know
Axial spondyloarthritis patients who received biologics-based treatment had less work and activity impairment than patients who did not receive biologics, according to a study in the Annals of the Rheumatic Diseases.
Page 28 of 34